home
portfolio
approach
team
careers
news
contact
investor portal

home
portfolio
approach
team
careers
news
contact
investor portal

Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005

Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005

Post navigation

Previous PostPrevious Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Next PostNext Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024

Search for:

Recent Comments

Archives

Categories

No categories

Meta

Log in
Entries feed
Comments feed
WordPress.org

© Nextech Invest Ltd. | privacy policy